Ozempic 1 MG/dose (4 MG/3 ML) 3ML
Ended Awarded Last action
- Contract number
- SPE2DR26F4E8L
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $108,046
Award facts
- Contract value 100% obligated
- $108,045.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $108,045.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp (UEI: KABZK8W6PQT3) on January 12, 2026, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, with an ultimate completion date of January 13, 2026. The contract represents a non-set-aside competitive award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026, which enables the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide.
AmerisourceBergen Drug Corp operates as a subsidiary of Cencora, Inc. (UEI: NWEGNLYTBDW4), a major pharmaceutical distributor and healthcare solutions provider. The parent company holds a significant Indefinite Delivery Contract with DLA valued at up to $999,999,999.00 through December 31, 2031. Both the subsidiary and parent entity have demonstrated extensive capability in fulfilling federal pharmaceutical procurement requirements across multiple therapeutic domains, including diabetes medications, specialty treatments, and critical medical supplies serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Quick answers
Who was awarded contract SPE2DR26F4E8L?
SPE2DR26F4E8L was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 12, 2026.
How much is contract SPE2DR26F4E8L worth?
The government has obligated $108,046 on SPE2DR26F4E8L.
Is contract SPE2DR26F4E8L an order under another contract?
Yes. SPE2DR26F4E8L is a delivery order under SPE2DR25D3012, an indefinite delivery contract.
Was contract SPE2DR26F4E8L competed?
The extent of competition for SPE2DR26F4E8L was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award